leisure time -WSS

leisure time

author：focus 2025-10-02 21:35:57 - browse：4278

Bill Cassidy speaks with his palm facing upward during a hearing on prescription drug costs — politics coverage from STAT — Sen. Bill Cassidy (R-La.) Kevin Dietsch/Getty Images

WASHINGTON — Republicans in Congress might try to use a technical maneuver to block the Biden administration from using so-called march-in rights to seize pharmaceutical patents and lower drug prices.

The Biden White House wants to ignore certain patents for inventions that were developed with government funding, at least in extenuating circumstances. Taxpayers have helped fund the research of a substantial number of drugs sold in the United States though the National Institutes of Health, so the proposal would let the government bring in generic drugmakers to make medicines even before their patents expire.

Until the Biden administration, the government refused to consider that an invention’s price could justify the “march in” maneuver. But the White House in December issued a draft framework for the NIH to more broadly use the power, including in cases where price is a concern.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： FDA's Woodcock to retire early next year

WSS

Does good food count as health care? Study aims to find out

Manchin, Huntsman team up to talk platform for 'unity' ticket that could run in 2024

Why police arrested suspected Gilgo Beach killer away from his house

CRISPR pioneers react to Casgevy, first gene

Congress: Eradicate hepatitis C and reduce the deficit

Congress: Eradicate hepatitis C and reduce the deficit

focus

leisure time

focus

How to save PrEP access — and even expand it

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

Continuity nursing helped my family in our darkest PICU moments

Who gets to use the title 'doctor'?

In Memoriam: Notable people who died in 2023

In key trial, Verve's treatment lowers cholesterol levels in patients

Novavax promises a turnaround & Lilly roils the obesity market

Argenx drug significantly slows progression of nerve disorder

Duchenne breakthrough therapy leaves behind pioneering families

Who gets to use the title 'doctor'?

hotspot

Celiac disease study examines precisely how gluten triggers injury

Can CDC director Mandy Cohen drive consensus in Washington?

Grail faces three suits alleging harassment, retaliation

Congress: Eradicate hepatitis C and reduce the deficit

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

J&J expands global access to TB drug amid advocacy campaign

focus

entertainment

focus

focus